OAM
SGMO

Oppenheimer Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Oppenheimer Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-26
Closed – – 1377
2020
Q1 		$0 Sell
26
-16,457
-100% -$122K ﹤0.01% 1621
2019
Q4 		$138K Buy
16,483
+617
+4% +$5.67K ﹤0.01% 1139
2019
Q3 		$144K Buy
15,866
+1,831
+13% +$20.5K ﹤0.01% 1111
2019
Q2 		$151K Buy
14,035
+1,003
+8% +$10.7K ﹤0.01% 1118
2019
Q1 		$124K Buy
13,032
+4,184
+47% +$42.7K ﹤0.01% 1156
2018
Q4 		$102K Buy
+8,848
New +$110K ﹤0.01% 1186
2017
Q4 		– Sell
-6,274
Closed -$94K – 1420
2017
Q3 		$94K Sell
6,274
-1,472
-19% -$16.3K ﹤0.01% 1218
2017
Q2 		$68K Buy
7,746
+415
+6% +$2.66K ﹤0.01% 1281
2017
Q1 		$38K Buy
+7,331
New +$29.4K ﹤0.01% 1395

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oppenheimer Asset Management's SGMO Position: Q2 2020 in Review

Oppenheimer Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2020, closing a stake of 26 shares.

Oppenheimer Asset Management first reported a position in SGMO in Q1 2017 and held it in 9 quarters. The position peaked at $151K in Q2 2019. 205 funds tracked by Wall St. Rank hold SGMO as of Q2 2020.

  • Oppenheimer Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2020 after selling out during the quarter.
  • Oppenheimer Asset Management sold 26 SANGAMO THERAPEUTICS INC shares in Q2 2020.
  • Oppenheimer Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2017 and held it in 9 quarters.
  • Oppenheimer Asset Management's SANGAMO THERAPEUTICS INC position peaked at $151K in Q2 2019.
  • 205 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2020.

Based on Oppenheimer Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.